InMed Pharmaceuticals Inc. (INM) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Price to Book (PBV) Ratio Undervalued price-to-book. INM stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) INM equity is higher than it's debt.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth INM has never had growing revenue.
Net Income Growth INM has never had growing net income.
Net Income INM never has positive net income for 2 years.
Dividend Yield INM has low dividend yield (0%).
Return of Assets INM has low return of asset (-131.23%).
Return of Equity INM has low return of equity (-169.59%).
Revenue INM never has positive revenue for 2 years.
Return of Invested Capital INM has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-15,622,866 USD

Dividend

Financial Ratios

CEO

CEO Name

Mr. Eric A. Adams

Management

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Additional Information

Company name

InMed Pharmaceuticals Inc.

Symbol

NASDAQ:INM

Exchange

NASDAQ Capital Market

Industry

Biotechnology

Sector

Healthcare

Address

815 West Hastings Street
Vancouver
BC
CA
V6C 1B4

Website

https://www.inmedpharma.com